Human hepatocellular carcinoma (HCC) is a rapidly increasing type of human cancer, ranked the eighth leading cause of cancer death in the United States. Although early diagnosis and surgical removal is a curative approach for some HCC cases, the majority are not resectable at the time of diagnosis due to lack of efficient early diagnosis and aggressive progression of the disease. Therefore, chemotherapy still remains the primary therapeutic choice for this disease. However, HCC is widely resistant to various cytotoxic antitumor agents, resulting in high patient mortality rates. Aldose reductase-like-1 (ARL-1), a novel protein overexpressed in 54% of human HCC tissues, can efficiently reduce the C13 methyl ketone group of daunorubicin to alcoholic form, daunorubicinol. Daunorubicinol possesses less antitumor activity, but stronger cardiomyopathic toxicity, compared to daunorubicin. Thus, we hypothesize that ARL-1 may represent a novel target to explore a new HCC chemotherapy strategy. This proposal is designed to answer the following questions: Does expression of ARL-1 within HCC tissues result in their drug resistance to anthracyclines? If so, how does this process occur? What is the pharmacokinetics of these agents in tumor tissues with high ARL-1 levels? Within tumors, what is the effect of high ARL-1 levels on the circulating metabolites with strong cardiovascular toxicity? These questions will be addressed through the following specific aims: (1) Determine the in vitro enzymatic activity of ARL-1 in catalyzing the reduction of the anthracyclines, with purified ARL-1 protein; (2) Determine the role of ARL-1 in the intracellular metabolism and antiproliferative activity of the anthracyclines, using ARL-1 gene targeting cell models; and (3) Evaluate the effect of tumor ARL-1 levels on the intratumoral metabolism and antitumor activity of the anthracyclines, using animal tumor models. Human hepatocellular carcinoma (HCC) is the most rapidly increasing type of human cancer in the United States. This disease carries high patient mortality rates, due to its wide resistance to current chemotherapy. Aldose reductase-like-1 (ARL-1) is a novel protein and a potential target for improved HCC chemotherapy treatment. This study will determine the role of ARL-1 in HCC drug resistance and its mechanisms of action, toward the pursuit of reducing HCC patient death. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA122327-01A1
Application #
7261164
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Song, Min-Kyung H
Project Start
2007-09-01
Project End
2009-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$144,500
Indirect Cost
Name
Southern Illinois University School of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
038415006
City
Springfield
State
IL
Country
United States
Zip Code
62794
Liu, Ziwen; Yan, Ruilan; Al-Salman, Ahmed et al. (2012) Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. Biochem J 442:273-82
Shen, Yi; Zhong, Linlin; Johnson, Stephen et al. (2011) Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem Biol Interact 191:192-8
Zhong, Linlin; Shen, Honglin; Huang, Chenfei et al. (2011) AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol Appl Pharmacol 255:40-7
Wang, Chun; Rajput, Sandeep; Watabe, Kounosuke et al. (2010) Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed) 2:515-26
Shen, Yi; Zhong, Linlin; Markwell, Stephen et al. (2010) Thiol-disulfide exchanges modulate aldo-keto reductase family 1 member B10 activity and sensitivity to inhibitors. Biochimie 92:530-7
Joshi, Amit; Rajput, Sandeep; Wang, Chun et al. (2010) Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10. Biol Chem 391:1371-8
Liu, Ziwen; Zhong, Linlin; Krishack, Paulette A et al. (2009) Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 437:39-44
Zhong, Linlin; Liu, Ziwen; Yan, Ruilan et al. (2009) Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem Biophys Res Commun 387:245-50
Liu, Jianghua; Wen, Gebo; Cao, Deliang (2009) Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat Anticancer Drug Discov 4:246-53
Wang, Chun; Yan, Ruilan; Luo, Dixian et al. (2009) Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 284:26742-8

Showing the most recent 10 out of 12 publications